Kimberly Manhard, Executive VP, Drug Development at HERON THERAPEUTICS, INC. /DE/ (HRTX), sold 494 shares at $30.62 ($15K) on 2018-11-02, disclosed to the SEC on 2018-11-02.
Scheduled sale ($15k) by Executive VP, Drug Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| INBX | BUY | 2024-08-30 | $140K | — | Filing → |
| HRTX | SELL | 2022-05-04 | $7K | — | Filing → |
| HRTX | SELL | 2021-05-04 | $27K | — | Filing → |